Philipp Koehler

Philipp Koehler

Auto-generated profile, based on publicly available information

Philipp Koehler

Department I of Internal Medicine, Center for Integrated Oncology (CIO), Medical Faculty and University Hospital of Cologne, University of Cologne

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
PKPhilipp Koehler
Philipp Koehler
MBMatteo Bassetti
Matteo Bassetti
ACArunaloke Chakrabarti
Arunaloke Chakrabarti
SCSharon Chen
Sharon Chen
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
OCOliver A. Cornely
Oliver A. Cornely

27 April 2020 in Mycoses
Verified
Journal Article
Open access
PDF file
PKPhilipp Koehler
Philipp Koehler
OCOliver A. Cornely
Oliver A. Cornely
Bernd BöttigerBernd Böttiger
Bernd Böttiger
FDFabian Dusse
Fabian Dusse
DEDennis A. Eichenauer
Dennis A. Eichenauer
ASAlexander Shimabukuro-Vornhagen
Alexander Shimabukuro-Vornhagen
Summary: Objectives: Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany.Methods: A retrospective chart review of all patients with COVID‐19 associated ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Cologne, Germany.Results: COVID‐19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS.Conclusion: Clinicians caring for patients with ARDS due to COVID‐19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co‐infection.

24 June 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
AAAmir Arastehfar
Amir Arastehfar
ACAgostinho Carvalho
Agostinho Carvalho
FVFrank van de Veerdonk
Frank van de Veerdonk
JJJeffrey D. Jenks
Jeffrey D. Jenks
PKPhilipp Koehler
Philipp Koehler
MHMartin Hoenigl
Martin Hoenigl
Like severe influenza, coronavirus disease-19 (COVID-19) resulting in acute respiratory distress syndrome (ARDS) has emerged as an important disease that predisposes patients to secondary pulmonary aspergillosis, with 35 cases of COVID-19 associated pulmonary aspergillosis (CAPA) published until June 2020. The release of danger-associated molecular patterns during severe COVID-19 results in both pulmonary epithelial damage and inflammatory disease, which are predisposing risk factors for pulmonary aspergillosis. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunity may, paradoxically, contribute to a highly permissive inflammatory environment that favors fungal pathogenesis. Diagnosis of CAPA remains challenging, mainly because bronchoalveolar lavage fluid galactomannan testing and culture, which represent the most sensitive diagnostic tests for aspergillosis in the ICU, are hindered by the fact that bronchoscopies are rarely performed in COVID-19 patients due to the risk of disease transmission. Similarly, autopsies are rarely performed, which may result in an underestimation of the prevalence of CAPA. Finally, the treatment of CAPA is complicated by drug–drug interactions associated with broad spectrum azoles, renal tropism and damage caused by SARS-CoV-2, which may challenge the use of liposomal amphotericin B, as well as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinetic and pharmacodynamic profiles.

14 October 2021 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
Livio PaganoLivio Pagano
Livio Pagano
JSJon Salmanton-García
Jon Salmanton-García
FMFrancesco Marchesi
Francesco Marchesi
Alessandro BuscaAlessandro Busca
Alessandro Busca
PCPaolo Corradini
Paolo Corradini
NANatasha Ali
Natasha Ali
Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.

2 January 2019 in Critical Reviews in Microbiology
Verified
Journal Article
Open access
DSDanila Seidel
Danila Seidel
AMArne Meißner
Arne Meißner
Michaela LacknerMichaela Lackner
Michaela Lackner
EPEllen Piepenbrock
Ellen Piepenbrock
JSJon Salmanton-García
Jon Salmanton-García
EVEdith Vermeulen
Edith Vermeulen
Invasive Scedosporium spp. and Lomentospora prolificans infections are an emerging threat in immunocompromised and occasionally in healthy hosts. Scedosporium spp. is intrinsically resistant to most, L. prolificans to all the antifungal drugs currently approved, raising concerns about appropriate treatment decisions. High mortality rates of up to 90% underline the need for comprehensive diagnostic workup and even more for new, effective antifungal drugs to improve patient outcome. For a comprehensive analysis, we identified cases of severe Scedosporium spp. and L. prolificans infections from the literature diagnosed in 2000 or later and the FungiScope® registry. For 208 Scedosporium spp. infections solid organ transplantation (n = 58, 27.9%) and for 56 L. prolificans infection underlying malignancy (n = 28, 50.0%) were the most prevalent risk factors. L. prolificans infections frequently presented as fungemia (n = 26, 46.4% versus n = 12, 5.8% for Scedosporium spp.). Malignancy, fungemia, CNS and lung involvement predicted worse outcome for scedosporiosis and lomentosporiosis. Patients treated with voriconazole had a better overall outcome in both groups compared to treatment with amphotericin B formulations. This review discusses the epidemiology, prognostic factors, pathogen susceptibility to approved and investigational antifungals, and treatment strategies of severe infections caused by Scedosporium spp. and L. prolificans.

15 February 2023 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
MHMartin Hoenigl
Martin Hoenigl
JSJon Salmanton-García
Jon Salmanton-García
MEMatthias Egger
Matthias Egger
Jean-pierre GangneuxJean-pierre Gangneux
Jean-pierre Gangneux
TBTihana Bicanic
Tihana Bicanic
CLClare Logan
Clare Logan